Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 20

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 20
---
 estimates, forecasts and projections about our business and the industry in which we operate and our management’s
beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties
and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this prospectus
may turn out to be inaccurate. Important factors that may cause actual results to differ materially from current expectations include,
among other things, those listed under “Risk Factors” and elsewhere in this prospectus. Potential investors are urged to
consider these factors carefully in evaluating the forward-looking statements.

The forward-looking statements included in this
prospectus speak only as of the date of this prospectus. Although we believe that the expectations reflected in the forward-looking statements
are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update or revise these
forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors
and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See “Where
You Can Find More Information.”

<div align='center'>8

USE OF PROCEEDS</div>

We will not receive any
proceeds from the sale of the common shares by the selling shareholders. All net proceeds from the sale of the common shares covered
by this prospectus will go to the selling shareholders. We expect that the selling shareholders will sell their common shares as described
under “Plan of Distribution.”

We may receive proceeds
from the exercise of the January 2024 PIPE Warrants to the extent that these warrants are exercised for cash by the selling shareholders.
The January 2024 PIPE Warrants, however, are exercisable on a cashless basis under certain circumstances. If all of the January 2024
PIPE Warrants mentioned above were exercised for cash in full, the proceeds would be approximately $2.4 million.

We intend to use the
net proceeds of such warrant exercise, if any, for general corporate purposes, which may include operating expenses, research and development,
including clinical and pre-clinical testing of our product candidates, working capital, future acquisitions and general capital expenditures.

The amounts and schedule of our actual expenditures
will depend on multiple factors including the progress of